ATRA Stock - Atara Biotherapeutics, Inc.
Unlock GoAI Insights for ATRA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $128.94M | $8.57M | $63.57M | $20.34M | N/A |
| Gross Profit | $107.93M | $-313,000 | $63.57M | $-261,661,000 | $-244,650,000 |
| Gross Margin | 83.7% | -3.7% | 100.0% | -1286.4% | N/A |
| Operating Income | $-83,438,000 | $-276,006,000 | $-280,513,000 | $-340,462,000 | $-309,052,000 |
| Net Income | $-85,403,000 | $-276,126,000 | $-228,302,000 | $-340,141,000 | $-306,620,000 |
| Net Margin | -66.2% | -3220.9% | -359.1% | -1672.3% | N/A |
| EPS | $-11.41 | $-65.18 | $-55.96 | $-90.78 | $-103.63 |
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis. In addition, it develops ATA368 program for patients with human papillomavirus associated cancers. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 9th 2023 | Evercore ISI | Downgrade | In-line | - |
| November 9th 2023 | H.C. Wainwright | Downgrade | Neutral | - |
| November 9th 2023 | Mizuho | Downgrade | Neutral | $1← $31 |
| July 20th 2022 | Citigroup | Downgrade | Sell | $3← $8 |
| July 13th 2022 | JP Morgan | Downgrade | Neutral | $10 |
| July 13th 2022 | Stifel | Downgrade | Hold | $5← $16 |
| May 10th 2022 | Citigroup | Downgrade | Neutral | $8← $15 |
Earnings History & Surprises
ATRAEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 13, 2026 | — | — | — | — |
Q1 2026 | Mar 6, 2026 | $-0.68 | — | — | — |
Q4 2025 | Nov 12, 2025 | $-0.83 | $-0.32 | +61.4% | ✓ BEAT |
Q3 2025 | Aug 11, 2025 | $-0.32 | $0.19 | +159.4% | ✓ BEAT |
Q2 2025 | May 15, 2025 | $-3.07 | $3.50 | +214.0% | ✓ BEAT |
Q1 2025 | Mar 7, 2025 | $-3.82 | $-1.19 | +68.8% | ✓ BEAT |
Q4 2024 | Nov 12, 2024 | $-3.77 | $-2.93 | +22.3% | ✓ BEAT |
Q3 2024 | Aug 12, 2024 | $-1.25 | $-3.10 | -148.0% | ✗ MISS |
Q2 2024 | May 9, 2024 | $-9.25 | $-5.75 | +37.8% | ✓ BEAT |
Q1 2024 | Mar 28, 2024 | $-15.25 | $-14.00 | +8.2% | ✓ BEAT |
Q4 2023 | Nov 1, 2023 | $-15.75 | $-16.50 | -4.8% | ✗ MISS |
Q3 2023 | Aug 8, 2023 | $-16.25 | $-17.00 | -4.6% | ✗ MISS |
Q2 2023 | May 8, 2023 | $-10.00 | $-18.00 | -80.0% | ✗ MISS |
Q1 2023 | Feb 8, 2023 | $-15.25 | $-18.00 | -18.0% | ✗ MISS |
Q4 2022 | Nov 8, 2022 | $-19.50 | $-20.50 | -5.1% | ✗ MISS |
Q3 2022 | Aug 8, 2022 | $-22.75 | $-7.75 | +65.9% | ✓ BEAT |
Q2 2022 | May 5, 2022 | $-24.50 | $-21.75 | +11.2% | ✓ BEAT |
Q1 2022 | Feb 28, 2022 | $-15.00 | $-24.00 | -60.0% | ✗ MISS |
Q4 2021 | Nov 4, 2021 | $-23.00 | $-22.50 | +2.2% | ✓ BEAT |
Q3 2021 | Aug 9, 2021 | $-22.00 | $-22.75 | -3.4% | ✗ MISS |
Latest News
Canaccord Genuity Maintains Buy on Atara Biotherapeutics, Raises Price Target to $25
📈 PositiveAtara Biotherapeutics Q3 EPS $(0.32) Beats $(0.86) Estimate, Sales $3.453M Beat $1.398M Estimate
📈 PositivePierre Fabre Pharmaceuticals Takes Over Tabelecleucel BLA From Atara Biotherapeutics Ahead Of FDA Priority Review On January 10, 2026 For First U.S. EBV+ PTLD Therapy
📈 PositiveAtara Biotherapeutics' Greg Ciongoli To Assume The Role Of Chair Of The Board Of Directors
➖ NeutralAtara gets FDA priority review for Tabelecleucel application
📈 PositiveAtara gains after insider purchase
📈 PositiveAtara Biotherapeutics to reduce workforce by 30%
📉 NegativeFrequently Asked Questions about ATRA
What is ATRA's current stock price?
What is the analyst price target for ATRA?
What sector is Atara Biotherapeutics, Inc. in?
What is ATRA's market cap?
Does ATRA pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to ATRA for comparison